Does EZETIMIBE Cause Hyperparathyroidism secondary? 11 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Hyperparathyroidism secondary have been filed in association with EZETIMIBE (Ezetimibe). This represents 0.1% of all adverse event reports for EZETIMIBE.
11
Reports of Hyperparathyroidism secondary with EZETIMIBE
0.1%
of all EZETIMIBE reports
11
Deaths
11
Hospitalizations
How Dangerous Is Hyperparathyroidism secondary From EZETIMIBE?
Of the 11 reports, 11 (100.0%) resulted in death, 11 (100.0%) required hospitalization.
Is Hyperparathyroidism secondary Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EZETIMIBE. However, 11 reports have been filed with the FAERS database.
What Other Side Effects Does EZETIMIBE Cause?
Myalgia (2,066)
Fatigue (876)
Drug ineffective (812)
Arthralgia (766)
Dyspnoea (766)
Nausea (742)
Dizziness (717)
Diarrhoea (688)
Headache (626)
Malaise (591)
What Other Drugs Cause Hyperparathyroidism secondary?
ESOMEPRAZOLE (1,357)
OMEPRAZOLE (1,274)
PANTOPRAZOLE (947)
LANSOPRAZOLE (888)
DEXLANSOPRAZOLE (382)
RABEPRAZOLE (108)
DENOSUMAB (60)
FUROSEMIDE (49)
OMEPRAZOLE\SODIUM BICARBONATE (48)
ESOMEPRAZOLE\NAPROXEN (47)
Which EZETIMIBE Alternatives Have Lower Hyperparathyroidism secondary Risk?
EZETIMIBE vs EZETIMIBE\ROSUVASTATIN
EZETIMIBE vs EZETIMIBE\SIMVASTATIN
EZETIMIBE vs EZOGABINE
EZETIMIBE vs FACTOR XIII CONCENTRATE
EZETIMIBE vs FAM-TRASTUZUMAB DERUXTECAN-NXKI